Clinical Trials
16 trialsNCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06051695 2026-05-26
EVEREST-2
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT03190941 2026-05-22
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05379985 2026-05-15
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT06128551 2026-04-23
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT03919292 2026-04-21
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Virginia Commonwealth University
Phase 1/2 Recruiting
NCT07213609 2026-03-23
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
Phase 1/2 Recruiting
NCT07462650 2026-03-10
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
Beijing Biotech
Phase 1/2 Recruiting
NCT07023731 2026-02-19
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
Phase 1/2 Recruiting
NCT07145255 2026-02-17
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
MBrace Therapeutics
Phase 1/2 Recruiting
NCT06682793 2025-09-09
DENALI-1
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT06530303 2024-11-05
BAH248
Essen Biotech
Phase 1/2 Recruiting
NCT06006390 2024-08-09
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Recruiting
NCT06270017 2024-02-21
ZEBRA-COLON
University Hospital, Linkoeping
Phase 1/2 Recruiting
NCT03985891 2020-12-17
JSFOL
Xiangya Hospital of Central South University
Phase 1/2 Recruiting